scholarly journals Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting

2020 ◽  
Vol 13 (6) ◽  
pp. 100771
Author(s):  
Renpei Kato ◽  
Daiki Ikarashi ◽  
Tomohiko Matsuura ◽  
Shigekatsu Maekawa ◽  
Yoichiro Kato ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Real World ◽  
Clinical Setting ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Clinical Safety ◽  
The Real ◽  
Asian Patients

Real-world evidence in metastatic renal cell carcinoma

2018 ◽  
Vol 104 (2) ◽  
pp. 76-82 ◽  
Author(s):  
Jeffrey Graham ◽  
Daniel YC Heng
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Real World ◽  
Renal Cell ◽  
Phase Iii ◽  
Advanced Renal Cell Carcinoma ◽  
First Line ◽  
Real World Data ◽  
The Real ◽  
Real World Evidence

Real-world evidence has played an important role in expanding our knowledge on the treatment and prognostication of advanced renal cell carcinoma. This type of data has been particularly helpful in providing a better understanding of groups that are traditionally excluded from randomized controlled trials. The International mRCC Database Consortium (IMDC) represents the largest collection of real-world data on patients with advanced kidney cancer treated with targeted therapies. The IMDC prognostic model has been used to stratify patients in contemporary clinical trials and to provide risk-directed treatment selection in everyday clinical practice. More recently, it has been shown to predict response to first-line combination immunotherapy in the phase III CheckMate 214 clinical trial. In this review, we highlight the real-world evidence associated with the treatment of mRCC. We focus on first-line therapy, as well as second-line and third-line therapeutic options, including novel immuno-oncology agents. We also address the real-world evidence for the use of cytoreductive nephrectomy in advanced renal cell carcinoma in the targeted therapy era.

Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with metastatic renal cell carcinoma (mRCC).

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 293-293
Author(s):  
Florence Marteau ◽  
Brooke Harrow ◽  
Christine McCarthy ◽  
Joel Wallace ◽  
Alisha Monnette ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Real World ◽  
Renal Cell ◽  
Response Rate ◽  
Checkpoint Inhibitors ◽  
P Value ◽  
The Real ◽  
The Us

293 Background: Checkpoint inhibitors (CPIs) are a treatment option for patients with metastatic renal cell carcinoma (mRCC), but there is limited clinical data on the efficacy of targeted therapies following CPI treatment. Cabozantinib is a tyrosine kinase inhibitor (TKI) that targets multiple receptor kinases implicated in tumorigenesis. In the US, cabozantinib is approved for use in patients with advanced RCC including after CPI treatment. Methods: This retrospective observational cohort study (NCT04353765) evaluated outcomes associated with cabozantinib or other TKIs (axitinib, lenvatinib, pazopanib, sorafenib, sunitinib) in patients with mRCC following CPI treatment. Eligible patients initiated TKI therapy between May 1, 2016 and Sep 31, 2019 and had received a CPI as their last systemic treatment prior to TKI therapy. Patients were identified from the US Oncology Network iKnowMed electronic health record database through structured queries and a targeted chart review. The following real-world outcomes were assessed: 6-month response rate (RR6months; primary); overall response rate (ORR); overall survival (OS); time to treatment discontinuation (TTD); rates of dose reductions, and discontinuation due to adverse events (AEs). The p value for RR6months was used to test for non-inferiority. Results: Eligible patients ( n = 247) had a mean (SD) age of 65.9 (10.5) years and 74.1% were male; 75.7% ( n = 187) received cabozantinib and 24.3% ( n = 60) received other TKIs. All patients had intermediate or poor MSKCC score; more poor-risk patients received cabozantinib than other TKIs (28.9% vs 20%). Outcomes data are shown in the Table. Compared with other TKIs, cabozantinib was associated with a significantly higher RR6months and ORR, and TTD was twice as long with cabozantinib. Discontinuation due to AEs was more frequent with other TKIs than with cabozantinib, although this was not statistically significant; 21.7% of discontinuations occurred during the first 3 months of treatment. AEs leading to discontinuation were consistent with the known safety profile of the products. Conclusions: In this mRCC population receiving routine care in the US, cabozantinib was used more frequently than other TKIs after CPI treatment. Cabozantinib was an effective and well tolerated option post-CPI, with a high response rate in the real-world setting.abozantinib was associated with a significantly higher response rate and a lower discontinuation rate due to AEs; TTD was double that of other TKIs. [Table: see text]

scholarly journals Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma

2019 ◽  
Vol 17 (3) ◽  
pp. e526-e533 ◽  
Author(s):  
Giuseppe Procopio ◽  
Aristotelis Bamias ◽  
Manuela Schmidinger ◽  
Robert Hawkins ◽  
Angel Rodriguez Sánchez ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Real World ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma

scholarly journals Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL study)

2018 ◽  
Vol 29 ◽  
pp. viii313
Author(s):  
G. Procopio ◽  
A. Bamias ◽  
M. Schmidinger ◽  
R. Hawkins ◽  
A. Rodriguez Sanchez ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Real World ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma

scholarly journals Erratum: Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

2014 ◽  
Vol 111 (12) ◽  
pp. 2383-2383 ◽  
Author(s):  
A B Suttle ◽  
H A Ball ◽  
M Molimard ◽  
T E Hutson ◽  
C Carpenter ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Clinical Safety ◽  
Safety And Efficacy

scholarly journals Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

2014 ◽  
Vol 111 (10) ◽  
pp. 1909-1916 ◽  
Author(s):  
A B Suttle ◽  
H A Ball ◽  
M Molimard ◽  
T E Hutson ◽  
C Carpenter ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Clinical Safety ◽  
Safety And Efficacy
Sign in / Sign up

Export Citation Format

Share Document